Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Angeli, M. Terzolo (2002)
Adrenal incidentaloma--a modern disease with old complications.The Journal of clinical endocrinology and metabolism, 87 11
D. Dworakowska, M. Korbonits, S. Aylwin, A. Mcgregor, A. Grossman (2011)
The pathology of pituitary adenomas from a clinical perspective.Frontiers in bioscience, 3
Todd Frieze, D. Mong, Maureen Koops (2002)
"Hook effect" in prolactinomas: case report and review of literature.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 8 4
W. Hall, M. Luciano, J. Doppman, N. Patronas, E. Oldfield (1994)
Pituitary Magnetic Resonance Imaging in Normal Human Volunteers: Occult Adenomas in the General PopulationAnnals of Internal Medicine, 120
M. Reincke, B. Allolio, W. Saeger, J. Menzel, W. Winkelmann (1990)
The 'incidentaloma' of the pituitary gland. Is neurosurgery required?JAMA, 263 20
P. Gilson, B. Crabb (2009)
Do apicomplexan parasite-encoded proteins act as both ligands and receptors during host cell invasion?F1000 Biology Reports, 1
L. Nieman, B. Biller, J. Findling, J. Newell-Price, M. Savage, P. Stewart, V. Montori (2008)
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism, 93 5
M. Fernández-Balsells, M. Murad, A. Barwise, J. Gallegos-Orozco, A. Paul, Melanie Lane, J. Lampropulos, I. Natividad, L. Perestelo-Pérez, Paula León‐Lovatón, Patricia Erwin, Jantey Carey, V. Montori (2011)
Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis.The Journal of clinical endocrinology and metabolism, 96 4
S. Ezzat, S. Asa, W. Couldwell, C. Barr, W. Dodge, M. Vance, I. McCutcheon (2004)
The prevalence of pituitary adenomasCancer, 101
G. Arnaldi, M. Boscaro (2009)
New treatment guidelines on Cushing's diseaseF1000 Medicine Reports, 1
J. Feldkamp, R. Santen, E. Harms, A. Aulich, Ulrich Mödder, W. Scherbaum (1999)
Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone‐secreting adenomas — results of a prospective studyClinical Endocrinology, 51
Dina Serhal, R. Weil, A. Hamrahian (2008)
Evaluation and management of pituitary incidentalomas.Cleveland Clinic journal of medicine, 75 11
A. Kanter, C. Sansur, J. Jane, E. Laws (2006)
Rathke's cleft cysts.Frontiers of hormone research, 34
N. Sanno, K. Oyama, S. Tahara, A. Teramoto, Y. Kato (2003)
A survey of pituitary incidentaloma in Japan.European journal of endocrinology, 149 2
S Ezzat, SL Asa, WT Couldwell (2004)
The prevalence of pituitary adenomas: a systematic reviewCancer, 101
A. Raappana, J. Koivukangas, T. Ebeling, T. Pirilä (2010)
Incidence of pituitary adenomas in Northern Finland in 1992-2007.The Journal of clinical endocrinology and metabolism, 95 9
E. Laws, A. Kanter (2011)
Rathke cleft cysts.Journal of neurosurgery, 101 4
S. Melmed, F. Casanueva, A. Hoffman, D. Kleinberg, V. Montori, J. Schlechte, J. Wass (2011)
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.The Journal of clinical endocrinology and metabolism, 96 2
K. Arita, A. Tominaga, K. Sugiyama, K. Eguchi, K. Iida, M. Sumida, K. Migita, K. Kurisu (2006)
Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination.Journal of neurosurgery, 104 6
A. Gruber, J. Clayton, S. Kumar, I. Robertson, Howlett Ta, P. Mansell (2005)
Pituitary apoplexy: retrospective review of 30 patients—is surgical intervention always necessary?British Journal of Neurosurgery, 20
G. Zada, N. Lin, Eric Ojerholm, S. Ramkissoon, E. Laws (2010)
Craniopharyngioma and other cystic epithelial lesions of the sellar region: a review of clinical, imaging, and histopathological relationships.Neurosurgical focus, 28 4
P. Day, M. Guitelman, R. Artese, León Fiszledjer, A. Chervin, Nicolas Vitale, G. Stalldecker, V. Miguel, D. Cornaló, Analia Alfieri, Mara Susana, M. Gil (2005)
Retrospective Multicentric Study of Pituitary IncidentalomasPituitary, 7
S. Melmed, A. Colao, A. Barkan, M. Molitch, A. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M. Vance, K. Ho, A. Giustina (2009)
Guidelines for acromegaly management: an update.The Journal of clinical endocrinology and metabolism, 94 5
P. Freda, A. Beckers, L. Katznelson, M. Molitch, V. Montori, K. Post, M. Vance (2011)
Pituitary Incidentaloma: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology and Metabolism, 96
P. Freda, K. Post (1999)
Differential diagnosis of sellar masses.Endocrinology and metabolism clinics of North America, 28 1
H. Buurman, W. Saeger (2006)
Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.European journal of endocrinology, 154 5
Pituitary incidentalomas are common lesions for which neurosurgical referrals may become progressively more frequent, given the increasing application of neuroimaging. The initial evaluation of a patient with radiographic evidence of an incidentaloma should focus on addressing two questions: (1) is the lesion causing neurological symptoms, and (2) is the lesion hormonally active? The answers to these two questions provide a framework for subsequent clinical management. The initial patient assessment should include a detailed history and physical examination, including the bedside assessment of visual fields. High-quality MRI imaging is essential, and formal visual field testing should be obtained in patients where the lesion abuts or compresses the optic apparatus. The initial biochemical workup is intended to assess potential pituitary hypo- or hyperfunction and should include measurement of serum levels of prolactin, insulin-like growth factor type-1, free thyroxine, testosterone, and an assessment of axis hypothalamic–pituitary–adrenal axis function. Additional testing may include serum thyroid-stimulating hormone, follicle-stimulating hormone, and luteinizing hormone levels. Neurologically-asymptomatic patients without endocrine dysfunction can be managed with observation at regular intervals, including MRI imaging at 6 months and 1 year and then annually for a period of 3 years. Follow-up biochemical assessment is not necessary in the absence of clinical symptoms or radiographic enlargement of the lesion. After 3 years the follow-up interval may be prolonged, although closer follow-up may be indicated for patients with lesions ≥1 cm. Most patients who either present with or who subsequently develop neurologic or endocrinologic symptoms should be considered for surgery as the first-line therapy.
Oncology Reviews – Springer Journals
Published: Oct 18, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.